PNC FINANCIAL SERVICES GROUP, INC. - GALECTIN THERAPEUTICS INC ownership

GALECTIN THERAPEUTICS INC's ticker is GALT and the CUSIP is 363225202. A total of 61 filers reported holding GALECTIN THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.0%.

Quarter-by-quarter ownership
PNC FINANCIAL SERVICES GROUP, INC. ownership history of GALECTIN THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$107,873
+33.3%
56,1840.0%0.00%
Q2 2023$80,905
-31.4%
56,1840.0%0.00%
Q1 2023$117,986
+85.8%
56,1840.0%0.00%
Q4 2022$63,488
-31.0%
56,1840.0%0.00%
Q3 2022$92,000
+24.3%
56,1840.0%0.00%
Q2 2022$74,000
-17.8%
56,1840.0%0.00%
Q1 2022$90,000
-6.2%
56,184
+21.7%
0.00%
Q4 2021$96,000
-46.4%
46,1840.0%0.00%
Q3 2021$179,000
+20.1%
46,184
-0.7%
0.00%
Q2 2021$149,000
+49.0%
46,529
+0.7%
0.00%
Q1 2021$100,000
-2.9%
46,1840.0%0.00%
Q4 2020$103,000
-43.1%
46,184
-32.1%
0.00%
Q3 2020$181,000
-13.0%
67,9680.0%0.00%
Q2 2020$208,000
+56.4%
67,9680.0%0.00%
Q1 2020$133,000
-31.4%
67,9680.0%0.00%
Q4 2019$194,000
-22.1%
67,9680.0%0.00%
Q3 2019$249,000
-7.8%
67,968
+4.6%
0.00%
Q2 2019$270,000
+12.0%
64,968
+37.7%
0.00%
Q1 2019$241,000
+48.8%
47,1640.0%0.00%
Q4 2018$162,000
-42.8%
47,1640.0%0.00%
Q3 2018$283,000
-14.8%
47,164
-9.6%
0.00%
Q2 2018$332,000
+36.6%
52,164
+1.9%
0.00%
Q1 2018$243,000
+42.1%
51,1840.0%0.00%
Q4 2017$171,00051,184
+25492.0%
0.00%
Q2 2016$0
-100.0%
200
-36.9%
0.00%
Q3 2015$1,0000.0%3170.0%0.00%
Q2 2015$1,0000.0%317
+74.2%
0.00%
Q1 2015$1,0001820.00%
Other shareholders
GALECTIN THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Cutter & CO Brokerage, Inc. 184,742$401,0000.10%
Geneos Wealth Management Inc. 511,606$2,261,0000.06%
SHEPHERD KAPLAN KROCHUK, LLC 12,000$26,0000.01%
OCCUDO QUANTITATIVE STRATEGIES LP 18,967$41,0000.01%
Vivaldi Capital Management LP 10,668$45,0000.01%
OSAIC HOLDINGS, INC. 1,221,984$2,651,0000.01%
CENTAURUS FINANCIAL, INC. 15,614$34,0000.00%
WEDBUSH SECURITIES INC 17,998$39,0000.00%
D.A. DAVIDSON & CO. 65,310$142,0000.00%
Virtu Financial LLC 14,683$32,0000.00%
View complete list of GALECTIN THERAPEUTICS INC shareholders